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Objective. To describe the epidemiology, clinical characteristics, and
management of Kawasaki disease in children in Hong Kong.
Design. Retrospective survey of medical records from July 1994 to June
1997, and prospective data collection from July 1997 to June 2000.
Setting. Hospitals with a paediatric unit in Hong Kong.
Patients. Patients diagnosed with Kawasaki disease between July 1994
and June 2000 in public hospitals in Hong Kong.
Main outcome measures. Incidence of Kawasaki disease and coronary
artery aneurysm rates.
Results. A total of 696 cases of Kawasaki disease were reported. There were
435 (62.5%) boys and 261 (37.5%) girls giving a male to female ratio of
1.7:1. The age ranged from 1 month to 15 years 5 months with a median of
1.7 years. Infants (<1 year) constituted the largest group of patients (223,
32.0%) and overall, 638 (91.7%) were younger than 5 years. Skin rash, con-
junctivitis, and oral signs were among the principal clinical features present
in over 80% of cases. Prominent cervical lymph nodes larger than 1.5 cm
were less commonly found (24%). Coronary artery aneurysms or ectasia
were present in 15.7% (109/696), 8.5% (59/696), and 5.0% (35/696) of pa-
tients at 2, 4, and 8 weeks, respectively. The incidence of Kawasaki disease
per 100 000 children under 5 years was significantly higher in the prospect-
ive study period than in the retrospective period (39 vs 26, P<0.001).
Conclusion. The incidence of Kawasaki disease is high in Hong Kong
and is 39 per 100 000 children below 5 years of age. The coronary artery
aneurysm prevalence is 5%. Intravenous gamma-globulin and high-dose
aspirin is the mainstay of treatment.
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Introduction
The syndrome of Kawasaki disease (KD) was first
described by Dr Tomisaku Kawasaki 38 years ago. It
was initially termed mucocutaneous lymph node
syndrome,1 and affects mainly children aged 5 years
or under. Diagnosis of KD remains an art: there is no
single diagnostic confirmatory test for the disease and
it can be camouflaged by the presenting features of
different viral infections. Diagnosis is thus based on
characteristic clinical signs and symptoms that are
classified as principal clinical findings. The congenial
interpretation of signs by experienced paediatricians
with the aid of other clinical and laboratory findings is
most important in the recognition of the disease and in
the institution of timely treatment. Accurate diagnosis
and early therapeutic intervention within 10 days of
onset of fever with high-dose aspirin and intravenous
γ-globulin (IVGG) can reduce the risk of developing
coronary artery abnormalities from 20%-30% to
5%-10%.2-8 Thrombosis within an aneurysm, myocar-
dial infarction, and death may occur in the acute
phase of the illness.9 Patients can also suffer long-
term morbidity as a result of scarring of coronary
arteries with stenosis, intimal thickening, and acceler-
ated atherosclerosis. Kawasaki disease is the lead-
ing cause of acquired heart disease in children in
Hong Kong.
The incidence of KD varies in different parts of
the world although it is most common in Asia. The
reported mean annual incidence per 100 000 children
below 5 years in Japan,10 the United States,11-13
Britain,14 and Australia15 were 110, 8.0 to 47.7, 3.6,
and 3.7, respectively. A retrospective study of the
incidence of KD in Beijing from 1995 to 1999 ranged
from 18.2 to 30.6 per 100 000 children below 5 years
old.16 Kawasaki disease was reported in Hong Kong
as early as 1985.17-19 Ten years ago the incidence in
Hong Kong, based on cases seen at one public
hospital between 1989 and 1994, was estimated to be
25.4 per 100 000 children below 5 years.20 There
was no territory-wide study and the Hong Kong
Kawasaki Disease Study Group (HKKDSG) was
subsequently formed to study the incidence and
characteristics of KD in Hong Kong.
Methods
The HKKDSG was formed in 1993 and comprised
paediatric cardiologists and paediatricians. A check-
list (Appendix 1) and a surveillance form (Appendix
2) with diagnostic criteria and questions on manage-
ment and clinical progress were designed and a retro-
spective survey of KD was carried out in 1997. Patients
diagnosed with KD between July 1994 and June 1997
were identified from a hospital audit database. Sur-
veillance forms were completed based on information
available in their hospital records. From July 1997 to
June 2000, prospective data collection was started in
all hospitals using the same documentation. Surveil-
lance forms were sent to the group for periodical audit
and review. This study summarises the surveillance
results of the 1994 to 1997 retrospective study and the
prospective data collected from 1997 to 2000.
There is no confirmatory diagnostic test for KD.
Diagnosis is based on recognition of five of the six
principal clinical features of the illness,21 which
include persistent fever, and in the absence of any
other obvious pathology:
1. Fever persisting for at least 5 days (many experts
believe that when the classic features are present,
KD can be diagnosed by experienced observers
before day 5);
2. Changes in extremities: acute phase—erythema and
oedema of the hands and feet; convalescent phase—
membranous desquamation of the fingertips;
3. Polymorphous exanthema;
4. Bilateral, painless bulbar conjunctival injection
without exudate;
5. Changes in lips and oral cavity: erythema and
cracking of lips, strawberry tongue, diffuse injec-
tion of oral and pharyngeal mucosae; and
6. Cervical lymphadenopathy (>1.5 cm in diameter).
Atypical or incomplete KD was diagnosed and
recorded on the surveillance form when three or
four of the principal criteria plus coronary ectasia22
were present. During the prospective study period,
echocardiography was performed at diagnosis, and
in the 2nd, 4th, and 8th week following the first day
of fever in compliance with the checklist guidelines.
Population data by age-group and sex for epide-
miological interpretation were obtained from the
Census and Statistics Department, Hong Kong. The
annual incidences of KD were calculated by dividing
the number of KD cases registered each year by the
population of children under 5 years old. Results
were analysed using the Statistical Package for
the Social Sciences (Windows version 11.5; SPSS
Inc, Chicago [IL], United States). Differences were
evaluated with the Chi squared test.
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Results
Over the 6-year period, a total of 696 cases of KD
were reported and only 10 (1.4%) were non-Chinese.
There were 435 (62.5%) boys and 261 (37.5%) girls
giving a male to female ratio of 1.7:1. The age range
was 1 month to 15 years 5 months with a median of
1.7 years. Of these 696 cases, 638 (91.7%) were
below 5 years; 223 (32.0%) were younger than
1 year; 415 (59.6%) were 1 to 5 years old; and 58
(8.3%) were older than 5 years. Infants formed the
largest group. The age and sex distribution is shown
in Fig 1. The frequency of the presenting signs
and symptoms is listed in the Table. Skin rash,
conjunctivitis, and oral signs were present in over
80% of cases whereas large cervical lymph nodes
were less common (24%). The presentation was
‘atypical’ in 72 (10.3%) patients, 36% of whom were
infants. A significantly higher percentage of infants
presented with atypical features compared with
children aged 1 to 5 years (21% vs 6%, P<0.001).
There were only six (1%) recurrences within 1 year.
Intravenous γ-globulin was administered as treat-
ment to 589 (84.6%) children. The starting dose was
1 g/kg in 146 (25%) patients and 2 g/kg in 443 (75%)
patients. Additional doses were given to 52 (7.5%)
patients with persistent or recurrent fever. Persistent
fever was defined as fever continuing 48 hours
after commencement of IVGG. Fever subsided within
12 hours in one third of patients receiving either
IVGG regimen although significantly more patients
remained febrile after 48 hours in the 1 g/kg group
(24% vs 10%, P<0.001). The prevalence of coronary
abnormalities at week 8 after onset of disease was
also higher in the 1 g/kg group (11.6% vs 3.5%,
P<0.0005).
The occurrence of KD was significantly higher in
the prospective study period than the retrospective
period (39 vs 26 per 100 000 children under the age
of 5 years, P<0.001).
Among all patients, coronary artery aneurysms (CAA)
or ectasia were present in 109 (15.7%), 59 (8.5%), and
35 (5.0%) patients in the 2nd, 4th, and 8th week,
respectively. Giant aneurysms (diameter ≥8 mm) were
present in three (0.4%) cases. There were no deaths.
The occurrence of KD was spread evenly over
the 6-year period (Fig 2) with peaks occurring in late
spring and summer and troughs in November to
December (late autumn and early winter when it is
dry and cool in Hong Kong).
Discussion
This is the first territory-wide epidemiological study
of KD in Hong Kong that compared retrospectively
and prospectively collected data. The study included
all cases from the public hospitals. Most patients
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Fig 2. Distribution of Kawasaki disease, 1994 to 2000
Table.  Proportion of principal clinical features of
patients with Kawasaki disease
Principal clinical feature No. of patients
Fever 651 (94%)
Rash 599 (86%)
Conjunctivitis 613 (88%)
Oral changes* 598 (86%)
QLip fissuring 393 (56%)
QStrawberry tongue 153 (22%)
QOral erythema 264 (38%)
Extremity changes* 504 (72%)
QOedema (hand) 265 (38%)
QErythema (palm) 222 (32%)
QDesquamation 206 (30%)
Cervical lymph nodes (>1.5 cm) 170 (24%)
* More than one clinical feature may appear in a patient
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diagnosed in the private sector with KD were referred
to a public hospital for evaluation, treatment, and
follow-up because of the high cost of echocardiography
and IVGG. Nonetheless it is possible that a few
cases may not have been reported, thus the true
incidence of KD in Hong Kong may be higher than
the 39 per 100 000 children below 5 years old reported
here. An incidence of 18.2 to 30.6 per 100 000
children younger than 5 years has been reported in
Beijing16 and 54.9 per 100 000 children younger
than 5 years in 1998 in Taiwan.23 This suggests
that the incidence of KD in Chinese population is
approximately one third to half of the Japanese and
much higher than in Caucasians.
The incidence of KD obtained in the two study
periods was significantly different (39 vs 26 per
100 000 children under the age of 5 years for prospect-
ive and retrospective study, respectively). This may
be due to different study methodologies, a genuine
increased incidence in the prospective study period,
or, more likely, an increased awareness of the
disease by primary physicians, paediatricians, and
cardiologists. Low reporting is the common reason
for a low incidence in the early years of reports and a
subsequent increased incidence equates to increased
awareness.
In this study the occurrence of KD peaked in the
spring and summer and was lower in autumn and
early winter (November to December). This is in
agreement with other series10 and with that reported
in China.16
As in other series, the presence of lymph nodes
as a presenting feature was less frequent than the
other principal features. The number of children who
presented with cervical lymph nodes was fairly low
and cervical lymph nodes larger than 1.5 cm in size
were only present in 24%. Notably, more children
had multiple cervical lymph nodes (n=308, 44%). It is
not known whether this is associated with clinical
characteristics. The Diagnostic Guidelines of Kawasaki
Disease produced in 2002 by the Japan Kawasaki
Disease Research Committee24 has modified the
statement that the sixth principal criteria is “acute
non-purulent cervical lymphadenopathy” and no longer
states a required size.
Coronary artery aneurysms or ectasia were present
in the 4th week in 8.5% (59/696) of children and in
5.0% at 8 weeks. This may be because some investi-
gators used a protocol that required echocardiography
to be performed at 2 and 8 weeks only. The checklist
used in this study recommended echocardiography at
week 4. This might have increased the number of
cases of ectasia and CAA (8.5%) diagnosed at 4
weeks, some of which had resolved by the 8th week
(5.0%). This is in accordance with the findings of a
Japanese study that reported no new lesions detected
by echocardiography between day 30 and 60 in 85
cases of KD.25 Another study of 91 patients in the
United Kingdom8 reported a maximum incidence of
coronary arterial lesions in the 4th week. It is im-
portant to perform echocardiography in the 4th week:
there are cases of transient dilatations in the early
stages at diagnosis and at 2 weeks that account for
the higher incidence of CAA in the acute stage that
peaks at around 4 weeks and gradually resolves at
8 weeks in the convalescent stage. The American
Heart Association (AHA) recommendation in 200426
to perform echocardiography at 2, 6, and 8 weeks for
uncomplicated cases of KD is similar to our practice.
Long-term echocardiographic follow-up of patients
in this study revealed further resolution of CAA or
ectasia in 6 months and up to 2 years.
Atypical KD or ‘incomplete KD’ accounted for
10% of patients. Such patients often present with
persistent fever but incomplete features of three or
fewer principal criteria. The diagnosis is often diffi-
cult and consultation with an expert is important.
Additional laboratory criteria may help confirm a
diagnosis (serum albumin, ≤3.0 g/L; anaemia for age;
elevated alanine aminotransferase; high platelet
count after 7 days, ≥450 000 /mm3; white blood cell
[WBC] count, ≥15 000 /mm3; and urine ≥10 WBC per
high power field). The 2004 AHA statement has
proposed a clinical algorithm that is most helpful for
the evaluation and treatment of ‘incomplete KD’.26
In the absence of specific diagnostic criteria for
KD, other diseases with similar clinical features
should be excluded (Box).26 Despite this, patients
previously diagnosed with measles, viral infections,
or scarlet fever have subsequently been found to have
KD. Therefore a high index of suspicion must be
maintained in a febrile child with rash.
Conclusion
Kawasaki disease is common in Hong Kong Chinese
children. This prospective study shows that the
incidence is 39 per 100 000 children below 5 years,
one third that of Japan. Intravenous γ-globulin together
with high-dose aspirin is the mainstay of treatment.
The CAA prevalence is 8.5% at 4 weeks and 5.0%
at 8 weeks even with IVGG treatment. Additional
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echocardiography should be performed at 4 weeks
to detect CAA or ectasia during the subacute stage of
the disease. Atypical KD occurs mainly in infants and
accounted for 10% of all cases.
Appendices
Additional material related to this article can be found
on the HKMJ website. Please go to <http://www.hkmj.
org.hk>, search for the appropriate article, and click
on Full Article in PDF following the title.
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Differential diagnosis of Kawasaki disease—diseases
and disorders with similar clinical findings
Viral infections (eg measles, adenovirus, enterovirus,
Ebstein-Barr virus)
Scarlet fever
Staphylococcal scalded skin syndrome
Toxic shock syndrome
Bacterial cervical lymphadenitis
Drug hypersensitivity reactions
Stevens-Johnson syndromes
Juvenile rheumatoid arthritis
Rocky mountain spotted fever
Leptospirosis
Mercury hypersensitivity reaction (acrodynia)
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Appendix 1. Checklist for Kawasaki disease
Checklist for Kawasaki disease Hospital No.: ………………………………………………
Name: ………………………………………………………
Hong Kong Kawasaki Disease Study Group I.D. No.: ……………… Sex: ……………… Age: …………
Team: ……………… Ward: ……………… Bed: …………
I. Clinical findings Onset Disappearance
A. 1. Fever persisting for more than 5 days ____________________ ____________________
2. Non-purulent conjunctival injection ____________________ ____________________
3. Mouth changes: ____________________ ____________________
(a) erythema of oral and pharyngeal cavity ____________________ ____________________
(b) fissuring of lips ____________________ ____________________
(c) strawberry tongue ____________________ ____________________
4. Extremity changes: ____________________ ____________________
(a) oedema of hand / feet ____________________ ____________________
(b) erythema of palm / sole ____________________ ____________________
(c) desquamation of finger tips and toes ____________________ ____________________
5. Exanthem (polymorphous, macular,
non-bullous, non-crusting) spreading from ____________________ ____________________
extremity to trunk ____________________ ____________________
6. Lymphadenopathy ____________________ ____________________
B. 1. Vomiting / diarrhoea ____________________ ____________________
2. Arthritis / arthralgia ____________________ ____________________
3. Tachycardia / CHF ____________________ ____________________
4. Obstructive jaundice ____________________ ____________________
5. Aseptic meningitis ____________________ ____________________
6. Pyuria / urethritis ____________________ ____________________
7. Others ____________________ ____________________
II. Laboratory data Date: _______________ _______________ _______________ _______________
ESR* _______________ _______________ _______________ _______________
WBC _______________ _______________ _______________ _______________
Platelet _______________ _______________ _______________ _______________
Hb _______________ _______________ _______________ _______________
Albumin _______________ _______________ _______________ _______________
C-reactive protein* _______________ _______________ _______________ _______________
ALT _______________ _______________ _______________ _______________
Monospot* _______________ _______________ _______________ _______________
Throat swab* _______________ _______________ _______________ _______________
Blood culture _______________ _______________ _______________ _______________
ASOT* _______________ _______________ _______________ _______________
Virus Study* throat swab, rectal swab _______________ _______________ _______________ _______________
* optional
III. Ultrasound findings Date: _______________ _______________ _______________ _______________
Coronary artery aneurysms at diagnosis 2 wks after onset 4 wks 8 wks
LCA (in mm) _______________ _______________ _______________ _______________
RCA (in mm) _______________ _______________ _______________ _______________
Pericardial effusion _______________ _______________ _______________ _______________
Hydrops of gall bladder _______________ _______________ _______________ _______________
Others _______________ _______________ _______________ _______________
IV. Treatment Started on Ended on
Aspirin 30 mg/kg/day ____________________ ____________________
3-5 mg/kg om ____________________ ____________________
IVGG 2 g/kg I.V. over 10-12 hours ____________________ ____________________
or 1 g/kg I.V. over 6 hours ____________________ ____________________
Others * ____________________ ____________________ ____________________
(i) Blood pressure measured (may have hypertension)
(ii) Palpate all peripheral arteries for obvious aneurysms
(iii) ECG – on admission
– at discharge
– at 2 months after discharge
(iv) CBP, platelet on admission, at discharge, every 2 weeks until normal
(v) 2-dimensional echocardiography (2DE) to be done on:
Day 1 of diagnosis
2nd, 4th weeks and 8 weeks (if abnormal), then periodically until normal
(vi) Treatment:
(1) Initial: anti-inflammatory dose, aspirin 30 mg/kg/day in four divided doses
(2) Change to 3-5 mg/kg/day in one dose after the acute phase
(3) Maintain on this dose for 2 months or until platelet/aneurysms have returned to normal
V. OPD follow-up
Should not receive MMR and chicken pox vaccine until ≥6 months later.
Long-term follow-up – for those who have had aneurysm.
Coronary angiography for those who had giant aneurysm formation or symptoms/signs of myocardial ischaemia.
Ng et al
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Appendix 2. Surveillance form
Surveillance of Kawasaki disease in Hong Kong
(Hong Kong Kawasaki Disease Study Group)
1. Name of patient: (initials e.g. CKM for Chan Ka Mei) ______________________________________________________
2. Sex: _____________ 3. DOB (ddmmyy): _______________________________________________________
4. Race: Chinese (C) non-Chinese (NC)
5. District (e.g. Shatin, Mongkok, Wanchai, etc.): __________________________________________________________
6. Name of Doctor i/c: _____________________________ Tel of Doctor i/c: _____________________________
7. Name of Hospital: ______________________________ Hospital No.: ________________________________
8. Date of fever onset (ddmmyy): ________________________________________________________________________
9. Diagnostic criteria Please tick (description if any)
1. Fever >5 days _________________________________________________________
2. Rash _________________________________________________________
3. Conjunctivitis _________________________________________________________
4. Mouth changes fissured/bleeding lips
strawberry tongue
erythema of oral or pharyngeal cavity
5. Extremity changes oedema of hand/feet
erythema of palm/sole
desquamation of finger tips and toes
6. Lymphadenopathy Cx lymph node >1.5 cm
multiple Cx Lns
10. Other significant presenting features: _________________________________________________________________
11. Coronary artery aneurysms (infants >2.0 mm; beyond infancy >3.0 mm):
Yes with ectasia aneurysm ; No
At 2 wks after onset: Yes RCA size_____mm; LCA size_____mm No
At 4 wks after onset: Yes RCA size_____mm; LCA size_____mm No
At 8 wks after onset: Yes RCA size_____mm; LCA size_____mm No
12. IVGG: given not given <D10 >D10 ( Day_____ )
2 g/kg iv infusion 1 g/kg iv infusion
400 mg/kg/dose x 5 days iv infusion others _________
13. How soon to become afebrile after starting IVGG? <12 hr <24 hr <48 hr >48 hr
Please fax this sheet to HKKDSG, Fax: 2384 5204; Tel: 2958 6741.
From HKKDSG, Convenor: Dr Ng Yin Ming Hon. Secretary: Prof Rita Sung
